TropMed Sponsored Research Funding Opportunities: this blog is designed to alert TropMed researchers to funding opportunities to support their research. The Research Administration Unit of the Office of Research Services (ORS) is here to help staff members with all application, grant management, and post-grant processes. Please contact Mr. Paul Adams or Mr. Oiko Tacusalme on ext. 1332 for more information, or to express interest in any of these grant opportunities.
Tuesday, August 6, 2013
NIAID Grant Opportunities Reminder: Parent R01, R03, R21
Reissued Parent Funding Opportunities
- PA-13-302, Research Project Grant (Parent R01)
Funding Opportunity Purpose
|
The Research Project Grant (R01) supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on descriptions of their programs.
|
R01 Application Due Dates 2013
| R01new | Research Grants |
October 5
|
- PA-13-304, Small Research Grant (Parent R03)
Funding Opportunity Purpose
|
The National Institutes of Health (NIH) Investigator-Initiated Small Research Grant (R03) funding opportunity supports small research projects that can be carried out in a short period of time with limited resources. The R03 activity code supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.
|
Funding Opportunity Purpose
|
The National Institutes of Health (NIH) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in categorical program areas. The R21 activity code is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.
|
R03, R21 Application Due Dates 2013
| R03, R21,new | Other Research Grants |
October 16
|
Wednesday, July 31, 2013
NCATS Therapeutics for Rare and Neglected Diseases (TRND) Program
Opportunity to Submit Proposals for the Therapeutics for Rare and Neglected Diseases (TRND) Program
Notice Number: NOT-TR-13-007
Key Dates
Letter of Intent/Pre-Application Call Due: No later than September 16, 2013
Final Proposal Submission Date: September 30, 2013
Issued by National Center for Advancing Translational Sciences (NCATS)
Purpose
The National Center for Advancing Translational Sciences (NCATS), Division of Preclinical Innovation (DPI) is announcing an open opportunity to submit proposals to collaborate with the Therapeutics for Rare and Neglected Diseases (TRND) program.
The TRND program performs preclinical and early clinical development of new drugs for rare and neglected tropical diseases, and develops new technologies and paradigms to improve the efficiency of therapeutic development for these diseases. The operational model of TRND is collaboration between intramural NCATS drug development scientists and partners having promising leads and disease/target knowledge, but lacking the expertise or resources to develop these projects into clinical stage programs attractive to biopharmaceutical or other suitable organizations. TRND is establishing collaborations with researchers in the public and private sectors to together “de-risk” rare and neglected tropical disease drug development projects by accomplishing lead optimization through an Investigational New Drug (IND) application with the Food and Drug Administration (FDA), and in limited circumstances, proof-of-concept human studies.
This Notice is being provided to allow potential applicants sufficient time to contact the Solicitation Coordinator to discuss development of meaningful collaborations and responsive proposals. TRND utilizes a Letter of Intent (LOI)/pre-application teleconference process.
This announcement for collaboration will not use NIH activity codes. Details of the opportunity are below.
Research Initiative Details
TRND collaborative projects will be initiated at various stages of preclinical development, but no earlier than optimization of well-characterized leads, and no later than a new molecular entity (NME), new biologic entity (NBE), or repurposed drug in need of IND-enabling studies. Projects of interest will be at one of the following stages:
- Lead Optimization: Lead Op aims to identify and develop a potent, specific development candidate from among the preliminary series through initial medicinal chemistry. These early-stage candidates must include clear structure-activity relationships (SAR) in at least two structurally distinct chemical series or a well-defined biological lead; reproducible activity in primary and orthogonal assays; efficacy in an accepted animal model (or when not available, cellular model) of the disease; initial indications of favorable Absorption, Distribution, Metabolism, and Excretion (ADME) properties; and favorable head-to-head comparisons versus the prior art.
- New Molecular / Biologic Entity (NME / NBE): This will represent an advanced lead molecule, requiring completion of IND-enabling studies. At minimum, the selected candidate molecule will include clear efficacy data, good drug metabolism and pharmacokinetic (DMPK) properties, and initial non-GLP safety studies demonstrating absence of gross toxicities. Development candidates may require completion of IND-enabling pharmacokinetic / pharmacodynamic / toxicology / formulation studies.
- Repurposing: A repurposing candidate represents a drug previously approved by FDA for another indication, which has been shown to have efficacy in an animal model (or when not available, cellular model) of a rare or neglected tropical disease. Relying heavily on the previous indication data package, a repurposing candidate will be more advanced, in need of formulation, dose-finding, disease-specific toxicology, or other studies to allow clinical testing to commence.
- Platform Technology: These programs will seek development support for a therapeutic candidate directed toward a specific rare or neglected tropical disease indication, but will represent a technology platform with the potential to address a wider range of additional disorders and that can enable more efficient future development of other therapeutics. Both early- and later-stage projects will be considered, as described above.
The TRND program will partner with academic laboratories, not-for-profit organizations, and for-profit companies. Foreign organizations may also apply. TRND uses the online proposal management website, ProposalCentral (https://proposalcentral.altum.com/), to facilitate LOI and Application submission. Applicants must contact the TRND Solicitation Coordinator to complete the LOI and Application submission process. Submitted applications will be reviewed for scientific merit and technical feasibility, as well as program balance and availability of resources. Successful applicants will collaborate with TRND to create and implement a therapeutic development project plan. Note that this is not a grant or contract program. No extramural funding will be provided.
For more information about the TRND program, please visit the TRND website at http://www.ncats.nih.gov/trnd.html.
To ensure sufficient time to develop meaningful proposals, the LOI/discussion process must be completed by no later than September 16, 2013. The application deadline for the current cycle of the program is September 30, 2013.
Inquiries
Please direct all inquiries to:
Andre M. Pilon, PhD
Solicitation Coordinator
Therapeutics for Rare and Neglected Diseases (TRND)
Division of Preclinical Innovation (DPI)
National Center for Advancing Translational Sciences (NCATS)
National Institutes of Health (NIH)
Email: TRND@mail.nih.gov
Tuesday, July 30, 2013
Wellcome Trust: Pilot funding for cross-disciplinary research connecting environment, nutrition and health
The
deadline for concept notes is 27 August 2013
Small awards in the order of £250 000 (exceptionally up to £500 000) for up to two years
Small awards in the order of £250 000 (exceptionally up to £500 000) for up to two years
Aims of the awards
- These small awards are designed to open up research avenues that will ultimately lead to work with a significant impact on human health. Pilot projects may address any aspect of the interplay between health, environment and nutrition, but a focus on health is key. Projects are not required to cover issues related to both environment and nutrition.
- Our scoping work highlighted the explosion of data in the public and private domains, and the importance of harnessing its value for society. In recognition of this, we would particularly like to see proposals with the potential to unlock the power of data by making it more relevant, available, accessible and useful (e.g. by formatting to permit inter-linkage). The size of these awards makes them well suited to projects that exploit existing datasets or pilot novel approaches to data collection and exploration.
- Projects outside of this theme, but relevant to the Sustaining Health area in other ways, are also welcomed.
We expect these awards to stimulate collaborations and build capacity for interdisciplinary research. We believe that high-quality research in this area requires the development of new interdisciplinary and cross-sector partnerships, particularly between biomedical (including public health) researchers and those working in social, economic, environmental, climate, agricultural, development and computer sciences.
Eligibility
We welcome proposals from a broad range of disciplines and we particularly encourage applications from cross-sector collaborations, involving academic organisations, industry/business, non-governmental organisations and/or government agencies based in the UK and overseas.
Participating organisations may be located in any country, and the principal investigator may be employed in any sector.
- Institutions
Not-for-profit research institutions in the UK that are able to sign up to Wellcome Trust Grant Conditions are eligible to apply; this includes those funded by the Medical Research Council, Cancer Research UK or the Biotechnology and Biological Sciences Research Council. Institutions in other countries should contact us to confirm their eligibility.
- Companies
Commercial companies are eligible to apply, either as principal applicants or as collaborators. We fund commercial companies to meet our charitable objectives through programme-related investment (PRI). For further details, please seeour policy on PRI [Word 23KB]. Companies will normally be expected to sign up to specific terms relating to the scheme.
All applications will require clear arrangements for leadership and management of the project, whether this involves a single institution or consortium.
Application Process
You should complete a concept note [Word 79KB] and send it to sustaininghealth@wellcome.ac.uk. We encourage you to discuss the suitability of your proposal with us before you send your concept note.
We will review concept notes as we receive them. If we decide to invite a preliminary application, we will email you a preliminary application form by the end of August 2013. From this stage onwards, the process is by invitation only. Uninvited applications will not be considered.
If your preliminary application is shortlisted, we will invite you to submit a full application, which will be subject to international peer review.
Assessment criteria
Applications will be assessed using the following criteria:
- importance and relevance of proposed research questions
- track record of the applicants and co-applicants and their ability to deliver high-quality research
- collaborative nature of proposed project and demonstrable ability to bring together multiple disciplines
- potential to build multidisciplinary research capacity
- regional and national and international context of the application (as appropriate)
- plans for data management and sharing
- potential for attracting additional, longer-term support.
Application advice
Wellcome Trust staff are happy to advise you during the preparation of a proposal.
If it is adequately justified, modest equipment purchase and maintenance costs may be included in an application. Building or refurbishment expenditure will not normally be considered.
Applications may not include requests for academic institutional overheads.
The most common application queries are addressed by our FAQs.
For more information: http://www.wellcome.ac.uk/Funding/Technology-transfer/Awards/Sustaining-Health/index.htm
Wednesday, July 24, 2013
Thursday, July 11, 2013
TRF-CHE-SCOPUS Researcher Award 2013
 | |||||||||||||||||||||||||||
For more information on these awards, please contact TRF-CHE-Scopus Awards Secretariat at: Siripat@trf.or.th or Elsevier, Mr Lionel New at: l.new@elsevier.com
|
Thursday, July 4, 2013
NIAID Paylines, 3 July 2013 Update
NIAID Paylines for FY 2013
As of July 3, 2013, NIAID raised the FY 2013 paylines for R03 and R21. T32 payline remains interim at 14 overall impact score.
These paylines apply to applications reviewed for the September 2012, February 2013, and June 2013 Council meetings.
What is a "payline"?
A payline is a funding cutoff point for grant applications set each fiscal year after NIAID gets a budget, by balancing projected grant numbers, grant budgets, and money in the Institute's budget. NIAID initially sets paylines conservatively. Following the payline, the Institute funds most applications in percentile (for R01s only) or overall impact score order (for other grants) and may fund additional applications above the payline at the end of a fiscal year.
| Grant Types | Payline | Status | Description |
|---|---|---|---|
| R01 (non‑new PIs) | 8 percentile | Fiscal Year | Research Projects for established investigators |
| R01 (new PIs) | 12 percentile | Fiscal Year | Research Projects for new and early-stage investigators |
| F31 | 30 overall impact score | Fiscal Year | NRSA Individual Predoctoral Fellowships to Promote Diversity in Health-Related Research |
| F32 | 25 overall impact score | Fiscal Year | NRSA Postdoctoral Fellowships |
| K (except K99) | 26 overall impact score | Fiscal Year | Career Development Awards |
| R03 | 23 overall impact score | Fiscal Year | Small Grants |
| R15 | 20 overall impact score | Fiscal Year | Academic Research Enhancement Awards (AREA) |
| R21 | 23 overall impact score | Fiscal Year | Exploratory/Developmental Grants |
| R41, R42 | 26 overall impact score | Fiscal Year | STTR Phase I and II—Small Business Technology Transfer |
| R43, R44 | 22 overall impact score | Fiscal Year | SBIR Phase I and II—Small Business Innovation Research |
| T32 | 14 overall impact score | Interim | Institutional NRSA Training Awards |
Subscribe to:
Posts (Atom)